MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

• Status: Unknown status
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Research Center for Hematology, Russia
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• Refractory forms of acute leukemia, but in complete remission (CR)

• Second and third remission of acute leukemia

• 2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL)

• relapsed multiple myeloma

• advanced leukemia

Exclusion Criteria:

• ICU

• Mechanical ventilation